Life Sciences Tools and Services
Company Overview of WaveSense, Inc.
WaveSense, Inc. engages in the development, manufacture, and marketing of analytical nanotechnologies for use in cellular and molecular assay markets. The company offers EpiSep, a lateral flow separations platform that is used for the detection and characterization of live cells, proteins, and genes. It also provides EpiSep slides, super paramagnetic particles, conjugate antibodies, preserved tumor cells, buffers, start up kits, ready-to-use kits, and accessories. The company offers its products for drug discovery and rare cell detection in blood and bone marrow, as well as for infectious disease, bio-defense, veterinary diagnostic, and regenerative medicine test applications. Its products a...
15339 Barranca Parkway
Irvine, CA 92618
Founded in 1999
Key Executives for WaveSense, Inc.
Founder and Chief Technology Officer
Compensation as of Fiscal Year 2016.
WaveSense, Inc. Key Developments
WaveSense Appoints Jack L. McGinley as New Chairman
Sep 10 15
WaveSense appointed Jack L. McGinley as its new chairman. Prior to co-founding RoundTable Healthcare Partners in 2001, McGinley spent 30 years in senior management at Baxter International, departing as executive vice president. In addition, William W. Curtis was appointed chief executive officer to develop and implement the company's new strategic commercialization plan.
WaveSense, Inc. Announces Launch of a New Application that Targets, Enriches and Isolates Cells Obtained from DRE/DRM
Apr 2 15
WaveSense, Inc. announced the availability of the latest addition to its line of cell enrichment applications delivered through its patented EpiSep medical product line. The Cell Enrichment from Expressed Prostate Secretions application captures, enriches and isolates targeted cells contained in prostate secretions obtained through digital rectal examination (DRE) or digital rectal massage (DRM). The EPS application is an important new addition to the WaveSense's Urology application suite that already includes cell enrichment from urine. The Cell Enrichment from Expressed Prostate Secretions application is the latest addition to a growing list of EpiSep HStargeted cell enrichment and isolation applications, including its Cell Enrichment from Urine (Uro-1) and Cell Enrichment from Bone Marrow (CD138) applications.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries